 
Page 1 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
STUDY PROTOCOL  
 
 
“A Randomized, Prospective, Study Comparing Fortiva™ Porcine Dermis vs. Strattice™ 
Reconstructive Tissue Matrix in Patients Undergoing Complex Open Primary Ventral Hernia 
Repair”  
 
 
 
Protocol:  RTI-2015 -02 
 
Sponsor:   
RTI Surgical, Inc.  
[ADDRESS_332079]  
Alachua, FL [ZIP_CODE] -2650  
Telephone: (386) 418 -8888  
 
Medical Monitor:   
Lennox K. Archibald, MD, FRCP, DTM&H  
 
Project Manager:   
Sabrina Buzzerd  
Sr. Manager, Clinical Projects  
RTI Surgical, Inc.  
Telephone: 386 -418-8888  
Fax: 386 -418-1627  
 
 
Version:   
4.0 Amendment 3 
 
Date of Protocol:  June 8, 2016  
 
Proprietary Notice:   
The confidential information in this document is provided to you as an  
Investigator, potential Investigator, or Consultant for review by [CONTACT_10825], your staff, 
and the applicable Institutional Review Board (IRB)/Independent Ethics 
Committee (IEC). Your acceptance of this document constitutes agreement that 
you will not disclose th e information contained herein to others without prior 
written authorization from RTI Surgical, Inc.  
 
Ethics Statement:   
The study will be conducted according to the International Conference on 
Harmonization  guideline E6 (R1): Good Clinical Practice: Consolidated Guideline.  
 
  
 
Page 2 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
TABLE OF CONTENTS  
I.   Background  ................................ ................................ ................................ ................................ ................................ ...... 6 
1.1 Introduction  ................................ ................................ ................................ ................................ ................................ .... 6 
1.2 Rational e ................................ ................................ ................................ ................................ ................................ ........  7 
II. Study Design  ................................ ................................ ................................ ................................ ................................ ..... 7 
2.1 Treatments  ................................ ................................ ................................ ................................ ................................ ..... 7 
2.2 Surgical T echnique:  ................................ ................................ ................................ ................................ ........................  [ADDRESS_332080] Withdrawal and Discontinuation  ................................ ................................ ................................ ..... 14 
5.3.4     Replacements  ................................ ................................ ................................ ................................ ...............  15 
5.3.5     Sponsor or Regulatory Agency Termination of the Study ................................ ................................ .............  15 
VI. Study Visits  ................................ ................................ ................................ ................................ ................................ .... 15 
6.1   Baseline/Visit 1:  ................................ ................................ ................................ ................................ ...........................  15 
6.2   Visit 2 (Day of Surgery):  ................................ ................................ ................................ ................................ ...............  15 
6.2.1 Data to be collected intra -operatively:  ................................ ................................ ................................ .......................  15 
6.3   Visit 3 (Hospi[INVESTIGATOR_3849] -2 days):  ................................ ................................ ................................ .............................  16 
6.4   Visit 4 ([ADDRESS_332081] -Operative +/ -One Week):  ................................ ................................ ................................ ..........  17 
6.5   Visit 5 ([ADDRESS_332082] -Operative +/ -14 days):  ................................ ................................ ................................ .............  18 
6.6 Visit 6 ([ADDRESS_332083] -Operative +/ -28 days): ................................ ................................ ................................ ..........  18 
6.7   Visit 7 ([ADDRESS_332084] -Operative +/ -28 days):  ................................ ................................ ................................ ...........  19 
6.8   Visit 8 Phone Call Follow Up  ([ADDRESS_332085] -Operative +/ -28 days):  ................................ ................................ .......  20 
 
Page 3 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
6.9   Unplanned Visit  ................................ ................................ ................................ ................................ ...........................  20 
6.10 Schedule of Events:  ................................ ................................ ................................ ................................ .....................  22 
VII. Safety Assessments  ................................ ................................ ................................ ................................ ......................  23 
7.1 Safety Evaluations  ................................ ................................ ................................ ................................ ....................  23 
7.2 Adverse Event Reporting  ................................ ................................ ................................ ................................ ..........  23 
7.3 Serious Adverse Events ................................ ................................ ................................ ................................ .............  24 
7.4 Unanticipated Adverse Events/Unanticipated Serious Adverse Events  ................................ ................................ ... [ADDRESS_332086] Protection Requirements  ................................ ................................ ................................ ...................  25 
IX. Regulatory Requirements  ................................ ................................ ................................ ................................ ..............  26 
X. Investigator’s Responsibilities  ................................ ................................ ................................ ................................ ........  [ADDRESS_332087] Approval  ................................ ................................ ................................ ...........................  27 
XI. Data Handling and Quality Assurance  ................................ ................................ ................................ ...........................  27 
11.1 Case Report Forms (CRFs) and Data Clarification Forms (DCFs):  ................................ ................................ .................  27 
11.2 Monitoring of the Stu dy: ................................ ................................ ................................ ................................ .............  28 
11.3 Inspection of Records:  ................................ ................................ ................................ ................................ .................  28 
11.4 Regulatory Compliance:  ................................ ................................ ................................ ................................ ..............  28 
11.5 Advertising: ................................ ................................ ................................ ................................ ................................ .. 28 
11.6 Protocol Amendments:  ................................ ................................ ................................ ................................ ...............  29 
11.7 Adherence to Protocol:  ................................ ................................ ................................ ................................ ...............  29 
11.8 Records Retention:  ................................ ................................ ................................ ................................ ......................  29 
XII. Study Reporting Requirements  ................................ ................................ ................................ ................................ .... 30 
12.1 Serious Adverse Events:  ................................ ................................ ................................ ................................ ..............  30 
12.2 Continuing Annual Reviews:  ................................ ................................ ................................ ................................ ........  30 
12.3 Financial Disclosure:  ................................ ................................ ................................ ................................ ....................  30 
12.4  Sponsor Liability : ................................ ................................ ................................ ................................ .........................  30 
12.5  Investigator Documentation : ................................ ................................ ................................ ................................ ...... [ADDRESS_332088] Market Surveillance  ................................ ................................ ................................ ................................ ............  31 
XV. Investigator’s Final Report  ................................ ................................ ................................ ................................ ...........  [ADDRESS_332089]  ................................ ................................ ................................ ................................ .....................  32 
XVIII. Publication of Results  ................................ ................................ ................................ ................................ ................  32 
18.1  Meetings  ................................ ................................ ................................ ................................ ................................ ..... 32 
18.2  Journals  ................................ ................................ ................................ ................................ ................................ .......  32 
XIX. Study Registration  ................................ ................................ ................................ ................................ .......................  32 
XX. References  ................................ ................................ ................................ ................................ ................................ .... 33 
XXI. Investigator Signature [CONTACT_3490]  ................................ ................................ ................................ ................................ .........  34 
 
Page 4 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
PROTOCOL SIGNATURE [CONTACT_1783]   
 
“A Randomized, Prospective, Study Comparing Fortiva Porcine Dermis vs. Strattice  Reconstructive 
Tissue Matrix  in Patients Undergoing Complex  Open Primary Ventral Hernia Repair”  
  
Protocol Number:    RTI-2015 -02 
 
 
 
_________________________________________   
 
 
                       _______________________________________________  
Caroline Hartill  
Chief Scientific Officer  
Executive Vice President                         Date  
 
 
_________________________________________   
 
                       _______________________________________________  
Lennox K. Archibald, MD, FRCP, DTM&H  
Medical Director                         Date  
 
 
_________________________________________   
 
                       _____________________________ __________________  
Christie Blakely                         Date  
VP, Marketing   
 
 
_________________________________________   
 
                       _______________________________________________  
Robin Waite  
VP, Clinical Projects and Reimbursement                         Date  
 
 
__________________________________________   
 
                      _______________________________________________  
Grant Bochicchio, MD, MPH, FACS  
Principal Investigator, Washington University  
in St. Louis  
                       Date  
 
 
 
 
 
 
 
 
 
 
 
Page 5 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-[ADDRESS_332090] OF ABBREVIATIONS  
 
AE Adverse Event  
CFR Code of Federal Regulations  
CRF Case Report Form  
IEC Independent Ethics Committee  
FDA Food & Drug Administration  
GCP Good Clinical Practice  
ICF Informed Consent Form  
ICH-GCP International Conference on Harmonization – Good Clinical Practice  
IEC Institutional Ethics Committee  
IRB Institutional Review Board  
PI [INVESTIGATOR_272016] 6 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
I.   Background  
1.1 Introduction  
In hernia repair, implants of various materials are  often chosen as a means of reinforcing the tissue in the 
region of the herniation, and ensuring a greater likelihood of success, as measured by a lower incidence of 
recurrence. In primary closure, the recurrence rate has been cited as ranging from 24 to  66% [9,3,12] while 
the number has been reported as significantly lower when a n implant  was used for the repair. [11] 
The use of implants in hernioplasties has been well documented and for this reason it is often  a preferred 
procedure.  One of the more common types of material for the prostheses used in hernioplasties is 
polypropylene  implant , but the use of this material in contaminated fields is   controversial. In complex 
hernias, such as large or small bowel r esections, the surgical procedures are often potentially 
contaminating. Therefore, the use of certain materials such as polypropylene can be hazardous due to 
bacteria colonizing the mesh. [5]  In addition, in the case of a large abdominal wall defect the use of a 
prosthetic device i s mandatory, however it needs to be noted that it is not possible to use polypropylene in 
direct contact [CONTACT_272032]. [10,6] 
When using a n acellular  dermal matrix derived from porcine in complex hernias, positive surgical results 
have been shown with no observed recurrences, while wound infections observed after a mean follo w-up 
of 11.1 months showed no significant difference compared to primary closure. [1]  Shaikh (2007) has also 
reported that recurrence rates for porcine acellular dermal matrix are similar to the recurrence rates wh en 
using synthetic materials . [13]  A case study that used porcine acellular dermal matrix in a contaminated 
field, although limited in scope, has also shown positive surgical outcomes at one year post -surgery. [7]  In 
an exposed bowel, Chuo, et al (2008) has demonstrated positive outcomes in patients with a variety of 
surgical situations including exposed bowel, contaminated abdominal wound beds and around stomas. [2] 
These outcomes certainly seem to support the animal models which have shown that biologic grafts, in 
comparison to synthetic material, are able to c lear a Staphylococcus aureus contamination. [8]   
Complex hernias include those that have either been repaired before on multiple occasions, those 
associated with infections, or those that have resulted in bowel perforations or fistulas. Porcine acellular 
dermal matrices  (ADM ) have recently been proposed as a means  to offset the disadvantages of 
polypropylene synthetic implants , for example their inability to integrate into the patient’s tissue thus 
creating a site for bacteria to colonize,  and have since been used in humans for hernia repairs.  While the 
polypropy lene synthetic implants are permanent, the acellular dermal matrix  implants have been shown to 
incorporate into the host, with the implanted tissue remodeling to resemble the original tissue, both 
histologically as well as functionally.  The product we pla n to use is a porcine acellular dermal matrix  which 
will have been processed via the Tutoplast® Tissue Sterilization Process.   
Animal models have been used extensively to assess implantable materials generally and implants of 
various materials for soft-tissue reinforcement in particular, despi[INVESTIGATOR_272017]. [ADDRESS_332091], however, been 
clearly exposed recently by [CONTACT_272033] , Permacol™  
 
 
Page 7 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
(supplemental cross -linked; Covidien, New Haven, CT, [LOCATION_003]) and Strattice™ Reconstructive  Tissue Matrix 
(non-supplemental cross -linked; LifeCell Corporation, Bridgewater, NJ, [LOCATION_003]), in different animal models, 
with startlingly differing results. 12.13 Therefore, the extrapolation of results from animal data to the 
clinical context should be performed with caution. The choice of porcine acellular dermal matrices  by [CONTACT_272034] (www.ncbi.nlm.hih/gov/pmc/articles/PMC3956623/).  
1.[ADDRESS_332092] -market study compares t wo FDA cleared 
biologic hernia materials.  Fortiva™ porcine dermis, processed by [CONTACT_272035], Inc., a non -cross linked 
porcine dermis will be compared to Strattice™ Reconstructive Tissue Matrix by [CONTACT_272036], a non -cross linked 
porcine dermis for reinforcement during the single stage open reconstruction of abdominal wall defects. The 
primary outcome will be hernia recurrence at [ADDRESS_332093] been cleared for marketing and being investigated in accordance with its cleared 
indications and cleared labeling, the Study entitled “ A Randomized, Prospective Study  
Comparing Fortiva vs. Strattice in Patient s Undergoing Open Primary Ventral Hernia Repair”  is exempt from 
IDE regulations according to 21 CFR 812.2(c ) (2). 
A device, other than a transitional device, introduced into commercial distribution on or after May 28, 
1976, that FDA has determined to be su bstantially equivalent to a device in commercial distribution 
immediately before May 28, 1976, and that is used or investigated in accordance with the indications in the 
labeling FDA reviewed under subpart E of part [ADDRESS_332094] ex abdominal wall 
hernia repair.  The specific definition of this population is described in the Inclusion/Exclusion criteria.  
Participants must be able to participate in the informed consent process and be willing to adhere to the 
follow up required for th is two (2) year study.  The treatment includes hernia repair reinforcement with 
one of the  following two hernia repair meshes:  
• Fortiva™ Porcine Dermis  
• Strattice™ Reconstructive Tissue Matrix  
 
 
Page 8 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
Fortiva™ Porcine Dermis is an implantable device  comprised of non -crosslinked acellular  porcine dermis that 
has been processed  via the Tutoplast tissue sterilization process , terminally sterilized and is stored 
hydrated and ready to use.   The implant is designed to be used in soft tissue repair and pro vides a strong, 
biocompatible scaffold that incorporates into host tissue.  
Strattice™ Reconstructive Tissue Matrix is an acellular reconstructive tissue matrix designed to support 
tissue regeneration. It is derived from porcine dermis, which undergoes non -damaging proprietary 
processing that removes cells and significantly reduces the key component believed to play a major role in 
the xenogeneic rejection response.  
2.2 Surgical Technique:  
The major source of structural integrity and strength of the abdominal wall is provided by [CONTACT_272037]. The main paired abdominal muscles include the external oblique muscles, internal 
oblique muscles, transversus abdominis muscles, and rectus  abdominis muscles and their respective 
aponeuroses, which are interdigitated with each other, and provide core strength and protection to the 
abdominal wall viscera. The integrity of the abdominal wall is essential not only to protect the visceral 
structu res but also to stabilize the trunk and to aid trunk movement and posture.  
Complex abdominal wall defects, including incisional abdominal wall hernias, are a challenging 
surgical problem. Incisional hernias occur in 10 to 23 percent of open abdominal lapar otomies, with 
recurrence rates reported between 18 and 50 percent (deHartog, et al, 200814; Lowe et al. 200015, 
Sailes et al , 2011 16.). The Component Separation Technique (CST), a type of rectus abdominis muscle 
advancement flap, was first used to reconstitute the linea alba, reduce abdominal wall tension, and 
provide a dynamic abdominal wall in patients with large abdominal wall defects (Ramirez et al. 
199017). CST allows reconstruction of a large defect without requiring a free distant transposition flap 
(de Vries et al. 2003)18. The advantages of CST are that it restores structural support of the abdominal 
wall, provides stable vascularized soft tissue coverage, and optimizes aesthetic appearance of 
complex abdominal wall d efects and giant midline abdominal wall hernias (Shestak et al. 2000)19. In 
this protocol, abdominal wall mobilization will be conducted in an attempt to bring the fascia 
together. If this is unable to be completed with circumferential undermining, compone nt separation 
will be performed bilaterally.  
Patients will then be randomized 1:1 to one of two treatment assignments:  
• Fortiva™ Porcine Dermis retrorectus/underlay  
• Strattice™ Reconstructive Tissue Matrix retrorectus/underlay  
Procedure: After the abdominal wall mobilization is completed, and the Investigator determines that 
the primary fascial closure can be obtained, the assigned implant will be prepared according to the 
manufacturer's instructions and will be immediately avai lable for the surgery.  
 
 
 
Page 9 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-[ADDRESS_332095] 3 -5 cm of overlap of the defec t with normal tissue. (If this 
technique still does not allow for primary closure, the investigator may alternatively perform a 
posterior component separation (Novitsky et al. or anterior component separation as per the 
investigators decision).   
Please no te that the peritoneum will be closed prior to securing the implant with a running #0 Vicryl 
suture. Then utilizing a parachute technique, full thickness (through fascia and implant ) No. 1 PDS 
suture will be sewn in an interrupted fashion to implant . Pleas e note that two (2) sutures will be 
placed inferiorly in Cooper's ligament as well as two (2) sutures superiorly in the subcostal area with 
#1 PDS as appropriately needed to secure the implant  as per the investigator. A Central suture will 
also be placed t o ensure appropriate placement between these sutures. The investigator will be sure 
that the  implant  is sewn in with moderate tension. The overlying fascia will be closed with simple 
interrupted No.1 PDS suture in vertical mattress or Figure of 8s fashion (as per the investigator) over 
the biologic implant . If the fascia is not able to be entirely closed (a bridge of implant  exists without 
overlying fascia), the subject will be withdrawn from the study and will be considered a "screen 
failure". Data capture d up until this point will not be included in the primary analysis. Please note that 
if the retrorectus space is obliterated, the implant  may be placed beneath the peritoneum and again 
sewn in via a parachute technique with #1 PDS in a simple interrupted f ashion incorporating fascia, 
peritoneum and implant .   After the implant has been secured, the fascia is closed in vertical mattress 
fashion with #1 PDS over the implant . 
2.3 Study Duration  
Subjects will participate in this study for up to two (2) years.  Participants will be followed until hospi[INVESTIGATOR_272018]/contact[CONTACT_272038]/or study team member for follow up visits at 
six (6) weeks, three (3) months, six (6) months and  [ADDRESS_332096] has been 
diag nosed with a true hernia recurrence (either by [CONTACT_272039]), he/she will be followed 
only for the planned re -operation (if indicated) and details of the etiology of the recurrence will be 
captured in the subject's study binder (CRF), when a vailable. The subject will only be followed to capture 
information about the re -operation once a recurrence is diagnosed.  
2.4 Study Endpoints  
2.4.1     Primary Endpoints  
The primary objective of this study is to compare the incidence of true hernia recurrence (true defect in 
the implant  repair in which intra -abdominal contents are protruding thr ough the defect) at or before 1 
year between the Fortiva™ Porcine Dermis group compared with Strattice™ Reconstructive Tissue Matrix 
group.   
 
Page 10 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
2.4.2     Secondary Endpoints  
• Recurrent hernias (functional hernias) requiring surgical intervention  
• True recurrence at 24 months  
• Evidence of Eventration/Hernia Recurrence (Radiographic)  
• Fluid collection (Seroma, Hematoma)  
• Surgical Site Infections  
• Systemic Infections  
• Enterocutaneous Fistula  
• Dehiscence  
• Implant failure requiring partial or total removal  
• Patient satisfaction (using the SF -36 questionnaire) at Baseline, 3 months, 6 months, 12,  and 24 months.  
• Days to discharge  
• Pain measured using the Visual Analog Scale for discomfort at Baseline, 3 months, 6 months, 12 
months, and 24 months.  
• Patient contentment with the cosmetic results at 12 months, 24 months and/or at the time of study 
withdrawal except for patients who have been withdrawn due to recurrence.  
2.4.3     Safety Endpoints  
• Type of Adverse Events (volunteered and elicited).  
• Frequency of Adverse Events (volunteered and elicited).   
III. Statistical Design  
This study is a single -center prospective, randomized study evaluating Fortiva Porcine Dermis vs. Strattice  
Reconstructive Tissue Matrix in compl ex hernia repair.  Up to 120 total subjects will be randomized in a 1:1 ratio.   
3.1 Sample Si ze 
Patients will be randomized at a 1:1 ratio. A total of 120 patients, 60 Strattice and 60 Fortiva patients 
will be enrolled. This sample size will give the study a 95% significance level and 80% power and shall 
provide  preliminary data and benchmark evidence for direct comparison of two post -market biologic 
mesh materials when used as reinforcement in large abdominal hernias. The analysis also 
contemplates a 15 to 20% dropout rate for the primary outcome.  
Power analysis and sample size determination is based on Log -rank test for equality of recurrence rates 
over time during the study between groups. The hazard rates of recurrence are key quantities. Often the 
hazard rates are very hard to obtain. However,  based on the mathematical relationships of hazard function 
and recurrence function, we can derive the hazard rate from either of two related quantities which are  
 
Page 11 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
often reported in literature –(1)  the proportion of recurrence -free during the study period or (2 ) median 
recurrence -free  time,  from Kaplan -Meier product limit survival curve.   
3.2 Statistical Plan  
Given the 1:1 randomized nature of the clinical trial and to preserve the inherent characteristics of 
the randomizat ion, analysis by [CONTACT_7586] -to-treat (ITT) is chosen. This type of analysis compares the 
study groups in terms of the treatment to which they were randomly allocated, irrespective of the 
treatment they actually received or other trial outcomes. Regardless o f protocol deviations and 
participant compliance or withdrawal, analysis is performed according to the assigned treatment 
group. This type of analysis will also help to demonstrate if there is superiority of one mesh over the 
other.  
 
If there is no superio rity of one mesh over the other, analysis will be performed using the same outcomes 
to assess if there is equivalence between both meshes. This will demonstrate that there is no clinically 
significant difference between the two treatment arms.  
For statisti cal analysis, these outcomes can be classified into two measurement scales - continuous and 
categorical. For continuous outcome, mean and standard deviation, median and range for each group will 
be calculated. ANOVA will be used to compare the difference in  the means among the two groups when 
data are reasonably norma lly distributed. Otherwise, non -parametric ANOVA will be used. For categorical 
data, proportion will be obtained for each outcome, along with 95% CI derived from exact method. 
Difference in the proportions among the four groups will be compared using Fisher’s exact test.  
3.[ADDRESS_332097] ex abdominal wall hernia.  
The specific  definition of this population is described in the Inclusion/Exclusion criteria.   
Given the 1:1 randomized nature of the clinical trial and to preserve the inherent characteristics of 
the randomization, analysis by [CONTACT_7586] -to-treat (ITT) is chosen. This type of analysis compares the 
study groups in terms of the treatment to which they  were randomly allocated, irrespective of the 
treatment they actually received or other trial outcomes. Regardless of protocol deviations and 
participant compliance or withdrawal, analysis is performed according to the assigned treatment 
group. This type o f analysis will also help to demonstrate if there is superiority of one implant  over 
the other.  
If there is no superiority of one implant over the other, analysis will be performed using the same 
outcomes to assess if there is equivalence between both implants . This will demonstrate that there is no 
clinically significant difference between the two treatment arms.  
3.[ADDRESS_332098] been 
reported since the start of  the study.  While patient data (no personal identifiers, only subject number will  
 
Page 12 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
be included) will be un -blinded for this summary, this will only be for internal use at RTI and for appropriate 
regulatory or notified bodies. The patient and treating inde pendent reviewer will remain blinded 
throughout the course of this study.  
IV. Potential Risks  
The planned surgical intervention for the treatment of the ventral hernia is part of the routine clinical care 
for the patient.  Therefore, the surgical intervention itself is associated with several risks to the patient (e.g. 
infection, pain, etc.), howev er, the participation in this study is not associated with any additional risks that 
would not otherwise be encountered during the normal progression of treatment for this condition.  The 
hernia repair will follow standard of care with one of two FDA clear ed hernia repair implants for their 
intended applications.  
V. Study Participants  
Subjects will be identified by [CONTACT_87690]/or personnel assigned by [CONTACT_473], as patients 
with a large compl icated  ventr al hernia expected to be repaired with porcine derived dermal matrices .  The 
inclusion criteria for subject selection are designed to broadly capture the subset of patients where surgeons 
are already currently using porcine derived dermal matrices .  It is not intended to usurp clinical judgment, 
nor advocate that modifiable patient behaviors, like smoking, not be modified in order to include a subject.  
Rather the criteria are designed to be inclusive of patients with large, complex hernias, particularly th ose in 
patients without acute, but at greater risk for, surgical site infections.[ADDRESS_332099]. 
Informed consent will be administered by [CONTACT_093] (or designee).  
5.2 Eligibility Criteria  
5.2.1     Inclusion Criteria  
• 18 years of age or greater  
• Have a BMI < or equal to 40  
• Have a pre -operative estimated hernia defect of 200 cm2 OR multiple hernia defects whose 
combined area is ≥ an estimated 200 cm2.  Patients whose defects do NOT meet or exceed 200 
cm2 intra -operatively will be withdrawn from th e study and will be considered an intra -operative 
screen failure   
• Have no contraindications to the test material (s)  
• Have a life expectancy greater than 1 year in the opi[INVESTIGATOR_689]  
• Able to provide informed consent  
• Able and willing to return for scheduled study visits over [ADDRESS_332100] -operatively (following 
research related surgery)  
 
Page 13 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
5.2.2     Exclusion Criteria  
• < 18 years of age  
• Subject is determined to have an American Society of Anesthesiologists’(ASA) physical class of 4, 5, 
or 6 
• Have a B MI >40  
• Have a hernia estimated  to be <200 cm2 
• Have abdominal loss of domain such that the operation would be impractical or would adversely 
affect respi[INVESTIGATOR_272019]  
• Participation in an investigational drug or device study that would impact the safety or scientific 
integrity of this study (in the opi[INVESTIGATOR_272020]) 
within the past 6 weeks prior to enrollment into this tria l 
• Have active necrotizing fasciitis or any other known active local or systemic infection  
• Have a known collagen metabolism disorder or any medical condition that could interfere with 
normal tissue healing process as determined by [CONTACT_737]  
• Have a kn own active malignancy present and/or had chemotherapy 12 weeks prior to screening or 
planned chemotherapy within 12 weeks of enrollment with exception of BCC or SCC  
• Have known moderate to severe cirrhosis which in the opi[INVESTIGATOR_272021]  
• Have a life expectancy less than 1 year  
• Be unable to participate in the informed consent process  
• Be unable or unwilling to return for scheduled study visits over the [ADDRESS_332101] -operative 
assessment period   
• Received high dose s teroids (> -100mg of prednisone) within the past 6 weeks  
• Known tobacco use within the past [ADDRESS_332102] at time of admission  
(patients who chew tobacco may be included at the discretion of the surgeon)  
• Uncontrolled diabetes (i.e. known HbA1C value > 7% within the last 6 weeks)  
• History of drug addiction (recreational drugs, prescription drugs or alcohol) that in the 
Investigator’s opi[INVESTIGATOR_272022]/or the subject’s ability to 
complete the required f ollow up  
• Pregnancy and/or breastfeeding  
 
Page 14 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
• Enterocutaneous fistula  
• Ventral hernia repairs involving active infection  
• Planned use of external VAC dressing intra -operatively  
5.[ADDRESS_332103] number.  
5.3.2     Randomization  
Patients who are consented and enrolled in the study will be randomized  to receive either one of the t wo 
hernia repair implant interventions. Randomization  will be 1:1. Patient numbers were allocated to a study 
arm based on pre -established randomization tables. Randomization tables were created using 
ranblock.exe (Menne Biomed Software, Tübingen, [LOCATION_013]). Sealed envelopes were prepared with 
patient specific numbers and provided to the site. If a patient is withdrawn after they have been assigned 
a number, the envelope with the corresponding patient number will be considered non-transferable  and 
may not be forwarded to another patient. The subjec t will be blinded to their treatment arm, but the 
surgeon will not.  
The physician should NOT disclose the treatment to the subject .   
Having the investigator blinded to the treatment assignment prior to randomization reduces enrollment 
bias.    
5.3.[ADDRESS_332104]:  
i. Is in deviation of the protocol  
ii. Experiences a serious or intolerable AE  
iii. Develops symptoms or conditions listed in the exclusion criteria during the course 
of the study  
iv. Requests an early discontinuation for any reason  
Information regarding  all withdrawn or lost -to-follow -up subjects will be documented on the 
Study Disposition Form. Patients will either complete all the necessary study requirements or their 
participation in the study may prematurely end for one or more reasons. Patients will be 
considered "Withdrawn" due to: death, a concurrent illness t hat prohibits continued participation, 
the Investigator elects to withdraw the participant due to reasons listed above or because he/she 
voluntarily withdraws consent at any time during the study for any reason. Such withdrawals shall 
be documented on the Study Disposition Form. All available information concerning death or 
concurrent illness should be documented and evaluated for adverse event reporting. If the 
participant withdraws his/her consent, he/ she should  be asked (when possible and without 
coercio n) the reason for the decision and notified that data already collected will continue to be  
 
 
Page 15 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
part of the study as per the consent form he/she signed at the time of enrollment. No further 
study procedures will take place after the participant requests to b e withdrawn from the study.   
5.3.4     Replacements  
Subjects who prematurely discontinue may be replaced at the Sponsor’s discretion.  
5.3.5     Sponsor or Regulatory Agency Termination of the Study  
Although the Sponsor (RTI Surgical, Inc.) intends to comp lete the study, it reserves the right to discontinue 
the study at any time for clinical or administrative reasons, or if required by [CONTACT_272040].  
VI. Study Visits  
6.1   Baseline/Visit 1:   
After signing the approved ICF, subjects who agree to participate will have Visit 1, where eligibility  will be 
reviewed and the staff will perform the following:  
1. Review all inclusion/exclusion criteria  
2. Record demographic information  
3. Medical, Surgical, and Social history  
4. Review of systems with Physical Exam  
5. Vital Signs (including height and weight)  
6. Record concomitant medications ( Record medications  subject has been taking within [ADDRESS_332105] sitting and standing (when 
physically capable). For subjects who are not able to position themselves in a specific manner 
for the photograph due to physical limitations, the reason for this will be recor ded in the 
subject's study record and this will not be considered a protocol deviation.  
8. The patient will complete the following questionnaires, while the site staff will review these 
forms for completion:  
a. VAS  
b. SF 36  
6.2   Visit 2 (Day of Surgery):   
If the day of surgery is different from the baseline visit study staff will review all inclusion/exclusion criteria 
to ensure the participant remains eligible for enrollment.  The surgery visit must be completed within [ADDRESS_332106] be repeated.  
6.2.1 Data to be collected intr a-operatively :  
1. Documentation of indication for surgery (i.e. incisional hernia, r e-do hernia repair, etc.)  
2. Documentation of size and location of hernia defect  
3. Operative start and finish times  
4. Determine if the subject has an active infection and if so, subject is withdrawn from study 
and is considered a “screen failure”  
 
 
Page 16 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-[ADDRESS_332107]'s abdomen is unable to be closed primarily and if so, subject is withdrawn 
from study and is considered a "screen failure"  
 
 
6. Operative procedure details including all research related information (detail in OR Notes) 
***Make sure all details are documented in the OR note (i.e. sutures used and where, number 
of drains inserted and where, overlap, etc. when possible)  
7. Type and dimensions of graft used  
8. Product and serial numbers of graft used  
9. Fixation procedures  
10. Concomitant procedures  
11. Photographic doc umentation of graft placement prior to closure, post -closure  
12. Complications during surgery (note any and all complications including uncontrolled bleeding, 
subject becoming unstable, error with mesh placement, etc.) and record these events as 
AE/SAE's as ap plicable  
13. Medications given during surgery  
6.3   Visit 3 (Hospi[INVESTIGATOR_3849] -2 days):   
1. General physical examination and surgical site evaluation  
2.  Lateral and frontal photographs performed with subject sitting and standing (when 
physically capable). For subjects who are not able to position themselves in a specific 
manner for the photograph due to physical limitations, the reason for this will be re corded 
in the subject's study record and this will not be considered a protocol deviation  
3. Adverse events evaluation (graft failure, dehiscence, enterocutaneous fistulas, seromas, wound 
infection, systemic infections, bleeding, etc.)  
4. Return to OR for additional repair or graft removal (scheduled or date of return)  
5. Review Medications (After surgery only medications that could impact healing will be 
recorded including but not limited to steroids, antibiotics)  
6. Use of Wound V.A.C.® and reason for use  
7. Date (s) of drain(s) removal, reason for drain (s) removal (i.e. drains have been in place for 7 days 
and/or the 24 hour fluid collection is < 30 cc /day, or any other reason removed).  
8. Physical evaluation for hernia recurrence  
***Once  a subject has been diagnos ed with a true hernia recurrence (either by [CONTACT_272041]), he/she will be followed only for the planned re -operation (if indicated) and details 
of the etiology of the recurrence will be captured in the subject's study binder (CRF), when 
available. The subject will only be followed to capture information about the re -operation once a 
recurrence is diagnosed.  
 
Page 17 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
***There is no need  to capture mesh related data or to conduct follow up visits between the 
diagnosis of recurrence and the operation for the recurrence. If a participant is not scheduled for a 
re-operation, his/her study participation will end at this point and this informa tion will be 
documented on the CRF.  
9.  Clinical evidence of eventration, implant  failure, implant  related complications, etc. 
Photographs of the surgical site may be taken to document evidence of adverse events, 
eventration, implant  failure, implant  related complications, etc.  
6.4   Visit 4 ([ADDRESS_332108] -Operative +/ -One Week):   
General physical examination and surgical site evaluation  
1.  Lateral and frontal photographs performed with subject sitting and standing (when 
physically capable). For subjects who are not able to position themselves in a specific 
manner for the photograph due to physical limitations, the reason for this will be recorded 
in the subject's study record and this will not be considered a protocol dev iation  
2. Adverse events evaluation (graft failure, dehiscence, enterocutaneous fistulas, seromas, wound 
infection, systemic infections, bleeding, etc.)  
3. Return to OR for additional repair or graft removal (scheduled or date of return)  
4. Review Medications (Afte r surgery only medications that could impact healing will be 
recorded including but not limited to steroids, antibiotics)  
5. Use of Wound V.A.C.® and reason for use.  
6. Date(s) of drain(s) removal, reason for drain (s) removal (i.e. drains have been in place for  7 days 
and/or the 24 hour fluid collection is < 30 cc /day, or any other reason removed).  
7. Physical evaluation for hernia recurrence  
***Once  a subject has been diagnosed with a true hernia recurrence (either by [CONTACT_272041] ), he/she will be followed only for the planned re -operation (if indicated) and details 
of the etiology of the recurrence will be captured in the subject's study binder (CRF), when 
available. The subject will only be followed to capture information about t he re -operation once a 
recurrence is diagnosed.  
***There is no need  to capture implant  related data or to conduct follow up visits between 
the diagnosis of recurrence and the operation for the recurrence. If a participant is not scheduled 
for a re -operati on, his/her study participation will end at this point and this information will be 
documented on the CRF.  
8. Clinical evidence of eventration, implant  failure, implant  related complications, etc. 
Photographs of the surgical site may be taken to document evid ence of adverse events, 
eventration, implant  failure, implant  related complications, etc.  
 
 
 
 
Page 18 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
6.5   Visit 5 ([ADDRESS_332109] -Operative +/ -14 days):   
1. General physical examination and surgical site evaluation  
2.  Lateral and frontal photographs performed with subject sitting and standing (when 
physically capable). For subjects who are not able to position themselves in a specific 
manner for the photograph due to physical limitations, the reason for this will be re corded 
in the subject's study record and this will not be considered a protocol deviation  
3. Adverse events evaluation (graft failure, dehiscence, enterocutaneous fistulas, seromas, wound 
infection, systemic infections, bleeding, etc.)  
4. Return to OR for additi onal repair or graft removal (scheduled or date of return)  
5. Review Medications (After surgery only medications that could impact healing will be 
recorded including but not limited to steroids, antibiotics)  
6. Use of Wound V.A.C.® and reason for use.  
7. Date(s) of  drain(s) removal, reason for drain (s) removal (i.e. drains have been in place for 7 days 
and/or the 24 hour fluid collection is < 30 cc /day, or any other reason removed).  
8. Patient Satisfaction form (SF -36) 
9. Physical evaluation for hernia recurrence  
***Once  a subject has been diagnosed with a true hernia recurrence (either by [CONTACT_272041]), he/she will be followed only for the planned re -operation (if indicated) and details 
of the etiology of the recurrence will be captured in the subje ct's study binder (CRF), when 
available. The subject will only be followed to capture information about the re -operation once a 
recurrence is diagnosed.  
***There is no need  to capture implant  related data or to conduct follow up visits between 
the diagnos is of recurrence and the operation for the recurrence. If a participant is not scheduled 
for a re -operation, his/her study participation will end at this point and this information will be 
documented on the CRF.  
10. Clinical evidence of eventration, implant  failure, implant related complications, etc. 
Photographs of the surgical site may be taken to document evidence of adverse events, 
eventration, implant  failure, implant  related complications, etc.  
11. VAS 
6.6   Visit 6 ([ADDRESS_332110] -Operative +/ -28 days):   
1. General physical examination and surgical site evaluation  
2. Lateral and frontal photographs performed with subject sitting and standing ( when physically  
capable). For subjects who are not able to position themselves in a specific manner for the 
photograph due to physical limitations, the reason for this will be recorded in the subject's 
study record and this will not be considered a protocol deviation  
3. Adverse events evaluation (graft failure, dehiscence, enterocutaneous fistulas, seromas, wound 
infection, systemic infections, bleeding, etc.)  
 
Page 19 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
4. Return to OR for additional repair or graft removal (scheduled or date of return)  
5. Review Medications (After surgery  only medications that could impact healing will be 
recorded including but not limited to steroids, antibiotics)  
6. Use of Wound V.A.C.® and reason for use.  
7. Date(s) of drain(s) removal, reason for drain (s) removal (i.e. drains have been in place for 7 days 
and/or the 24 hour fluid collection is < 30 cc /day, or any other reason removed).  
8. Patient Satisfaction form (SF -36) 
9. Physical evaluation for hernia recurrence  
***Once  a subject has been diagnosed with a true hernia recurrence (either by [CONTACT_272042]), he/she will be followed only for the planned re -operation (if indicated) and details 
of the etiology of the recurrence will be captured in the subject's study binder (CRF), when 
available. The subject will only be followed to capture information  about the re -operation once a 
recurrence is diagnosed.  
***There is no need  to capture implant  related data or to conduct follow up visits between 
the diagnosis of recurrence and the operation for the recurrence. If a participant is not scheduled 
for a re -operation, his/her study participation will end at this point and this information will be 
documented on the CRF.  
10. Clinical evidence of eventration, implant  failure, implant  related complications, etc. 
Photographs of the surgical site may be taken to docum ent evidence of adverse events, 
eventration, implant  failure, implant  related complications, etc.  
11. VAS 
6.7   Visit 7 ([ADDRESS_332111] -Operative +/ -28 days):   
1. General physical examination and surgical site evaluation  
2.  Lateral and frontal photographs performed with subject sitting and standing (when 
physically capable). For subjects who are not able to position themselves in a specific 
manner for the photograph due to physical limitations, the reason for this will be recorded 
in the subject's study record and this will not be considered a protocol deviation  
3. Adverse events evaluation (graft failure, dehiscence, enterocutaneous fistulas, seromas, wound 
infection, systemic infections, bleeding, etc.)  
4. Return to OR for additional repa ir or graft removal (scheduled or date of return)  
5. Review Medications (After surgery only medications that could impact healing will be 
recorded including but not limited to steroids, antibiotics)  
6.   Use of Wound V.A.C.® and reason for use.  
7. Date(s) of drain(s) removal, reason for drain (s) removal (i.e. drains have been in place for 7 days 
and/or the 24 hour fluid collection is < 30 cc /day, or any other reason removed).  
8. Patient Satisfaction form (SF -36) 
9. Physical evaluation for hernia recurrence  
 
Page 20 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
***Once  a subject has been diagnosed with a true hernia recurrence (either by [CONTACT_272041]), he/she will be followed only for the planned re -operation (if indicated) and details 
of the etiology of the recurrence will be captured in the subject's st udy binder (CRF), when 
available. The subject will only be followed to capture information about the re -operation once a 
recurrence is diagnosed.  
***There is no need  to capture implant  related data or to conduct follow up visits between 
the diagnosis of r ecurrence and the operation for the recurrence. If a participant is not scheduled 
for a re -operation, his/her study participation will end at this point and this information will be 
documented on the CRF.  
10. Clinical evidence of eventration, implant  failure, implant  related complications, etc. 
Photographs of the surgical site may be taken to document evidence of adverse events, 
eventration, implant  failure, implant  related complications, etc.  
11. VAS 
12. Patient contentment with the cosmetic results  
6.8   Visit 8 Phon e Call Follow Up ([ADDRESS_332112] -Operative +/ -28 days ):  
1. Recurrence Information (ask participant if they have been evaluated and or treated for 
recurrence)  
2. Adverse events evaluation (graft failure, dehiscence, enterocutaneous fistulas, seromas, wound 
infection, systemic infections, bleeding, etc.)  
3. Return to OR for additional repair or graft removal (scheduled or date of return)  
4. Review Medications  (After surgery only medications that could impact healing will be 
recorded including but not limited to steroids, antibiotics)  
5. Use of Wound V.A.C.® and reason for use.  
6. Patient Satisfaction form (SF -36)* 
7. VAS* 
8. Patient contentment with the cosmetic results * 
*The subjective questionnaire s entitled Visual Analog Scale (VAS) , SF-36, and Patient Contentment  
cannot be completed visually by [CONTACT_423] . Therefore , for the VAS,  patients will be asked to rate their 
pain on a scale of 1 -10. Patients will be asked questions on the SF -36 and Patient Contentment and the 
answers will be transcribed  by [CONTACT_68293] .  
6.9   Unplanned Visit   
The procedures performed at an unplanned visit will depend on the nature of the  visit. The 
procedures suggested include:  
1. Physical assessment to include BMI, general health, etc. (if indicated)  
2. Physical examination of surgical site (if indicated)  
3. Lateral and frontal photographs performed with subject sitting and standing (when physically    
capable). For subjects who are not able to position themselves in a spe cific manner for the  
 
 
Page 21 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-[ADDRESS_332113]'s study 
record and this will not be considered a protocol deviation.  
5. Radiographic evidence of recurrence only if clinically indicated  
6. Newly diagnosed medical issues  
7. Medication updates, if any  
8.   Adverse events since last visit (i.e. graft failure, enterocutaneous fistula, seromas, wound 
infection, systemic infection, bleeding, etc.)  
9. Physical evaluation for hernia recurrence  
***Once  a subject has been diagnosed with a true hernia recurrence (either by [CONTACT_272041]), he/she will be followed only for the planned re -operation (if indicated) and 
details of the etiology of the recurrence will be captured in the subject's stu dy binder (CRF), 
when available. The subject's will only be followed to capture information about the re -
operation once a recurrence is diagnosed.  
***There is no need  to capture implant related data or to conduct follow up visits between the  
diagnosis of recurrence and the operation for the recurrence. If a participant is not scheduled for 
a re-operation, his/her study participation will end at this point and this information will be 
documented on the CRF.  
10.  Clinical evidence of eventration, implant failure , implant related complications, etc. 
Photographs of the surgical site may be taken to document evidence of adverse events, 
eventration, implant failure, implant related complications, etc.  
11.   Return for repair since last visit.  
12. Patient Satisfaction form (S F-36)* 
13.   VAS* 
14.  Patient contentment with cosmetic results * 
*IF the subjective questionnaires entitled Visual Analog Scale (VAS), SF -36, and Patient Contentment 
cannot be completed visually by [CONTACT_272043], patients will be asked to rate their pain on a 
scale of 1 -10. Patients will be asked questions on the S F-36 and Patient Contentment and the answers 
will be transcribed by [CONTACT_68293].  
 
 
 
 
Page 22 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
6.10  Schedule of Events:   
Schedule of Events  
 Visit 1  
Baseline  Visit 2  
Surgery  Visit 3  
Hospi[INVESTIGATOR_138007] 
(-2 days)  Visit 4   
6 Weeks 
(+/- 1 
week)  Visit 5  
    3  
Months 
(+/- 14 
days)  Visit 6  
    6 
Months 
(+/- 28 
days)  Visit 7  
   12 
Months  
(+/- 28 
days)     Visit 8  
Telephone  
 24 Months  
 (+/- 28 days)  
Informed 
Consent  X        
Physical Exam  X  X X X X X  
Medical, Social, 
Surgical History  X X       
Medications  X X X X X X X X 
Adverse Events   X X X X X X X 
SF36 * X    X X X X 
VAS* X    X X X X 
Clinical 
Evaluation  X  X X X X X  
Photographs  X X X X X X X  
Patient 
Contentment 
with cosmetic 
results*        X X 
 
*If withdrawn early  complete patient contentment cosmetic results.  
*If the subjective questionnaires entitled Visual Analog Scale (VAS), SF -36, and Patient Contentment cannot 
be completed visually by [CONTACT_423] , for the VAS, patients will be asked to rate their pain on a sc ale of 1 -
10. Patients will be asked questions on the SF -36 and Patient Contentment and the answers will be 
transcribed by [CONTACT_68293].   
 
Page 23 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-[ADDRESS_332114] -marketing trial, only adverse events  or serious adverse events that are 
related to the surgical procedure or device will be recorded. Safety will be assessed by [CONTACT_272044], intensity and duration of all device related adverse events (AEs) and their relationship to the 
device.  
7.2 Adver se Event Reporting  
An Adverse Event (AE) is defined as any untoward medical occurrence in a subject enrolled into this 
study, regardless of its causal relationship to treatment. The Investigator is responsible for recording all 
AEs related to the surgical procedure or the device that are observed or reported by [CONTACT_272045]. The collection of AE's shall begin immediately after the patient has had a 
porcine derived dermal matrix surgically implanted. AEs  related to the surgical procedure or the 
device  that occur from surgery through completion of the final follow -up visit, whether observed 
by [CONTACT_272046], shall be reported in de tail on the appropriate CRFs and 
followed to resolution or the end of the subject's study participation.  
In the event a subject reports an AE outside the scheduled clinical visit, it will be assessed at the 
earliest opportunity by [CONTACT_737].  
In fo llowing up AEs, attempts will be made to obtain as much information as possible about event 
evolution and outcome. Every effort will be made to follow the subject until resolution of the AE.  
Adverse Event/Serious Adverse Evaluation  
Degree of Impairment  
The Investigator will evaluate the relationship of the adverse event to the degree of impairment 
using the following:  
1. Mild: The AE is transient and easily tolerated by [CONTACT_423] ; no limitation of usual 
activities  
2.   Moderate: The AE causes the subject discomfort and interrupts the subject's normal 
activity ; some limitation of usual activities  
3.    Severe: The AE is life threatening, results in permanent impairment of a body function, 
causes permanent damage to a body structure, or necessitates medical or surgical 
intervention to preclude permanent impairment of a body function or permanent 
damage to a body structure ;  inability to carry out usual activities  
Relationship of AE/ SAE to Implant  
The Investigator will evaluate the relationship of the AE/SAE to the use of the implanted mesh according 
to the following:  
 
Page 24 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
1. Definite: The AE/SAE follows a reasonable temporal sequence from the 
implantation of the implant  and/or is directly attributable to the use of the implant  
within the repair site.  
2. Possible: The A E/SAE follows a reasonable temporal sequence following the 
implantation of the implant  and the possibility of the implant 's involvement cannot 
be excluded. However, other factors related to the surgical procedure, underlying 
disease, concomitant treatment or medications are presumable.  
3. Unlikely: The AE/SAE has an improbable temporal sequence from the implantation of 
the implant  or it can be reasonably explained by [CONTACT_1604], including surgical 
procedure, underlying disease, concomitant treatment or medi cations.  
4. Not Related: The AE/SAE has no temporal sequence from the implantation of the 
implant  or it can be explained by [CONTACT_1604], including surgical procedure, underlying 
disease, concomitant treatment or medications.  
For the purposes of this study, significant adverse events will be documented and reported to the 
study PI , Sponsor, and  appropriate oversight committee  at the institution per institutional protocol  
7.3 Serious Adverse Events  
An Adverse Event is serious if:  
• It results in death  
• It is life threatening (the subject is at immediate risk of dying from the adverse experience)  
• It requires inpatient hospi[INVESTIGATOR_72010]  
• It results in persistent or significant disability/incapacity  
• Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_3767] a serious adverse device effect when, based upon 
appropriate medical judgment, they may jeopardize the subject and may require medical 
or surgical intervention to preven t one of the outcomes listed in this definition  
SAEs will be recorded in the CRF if they occurred as follows:  
After a subject received treatment and throughout the subject’s follow -up period.  After the subject’s 
follow -up period, and for which a causal relationship to treatment with either randomization group 
cannot be ruled out.  Follow -up period is defined as the protocol -stipulated period or, for subjects 
prematurely withdrawn from a study, the duration of subject’s participation .   
Study staff  are in structed to report all SAEs to the PI [INVESTIGATOR_272023] 24 hours of becoming aware 
of the SAE. All  follow -up SAE reports are to be completed and provided within 7 calendar days  to the 
Sponsor , allowing time for more complete reports.  
 
Page 25 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
All Serious Adverse Events (SAEs) must be reported to:  
Clinical Projects  
RTI Surgical, Inc.  
[ADDRESS_332115]  
Alachua, FL [ZIP_CODE] -2650  
(P) 386 -418-8888  
(F) 386 -418-1627 and 
RTI Customer Service  
[PHONE_5664]  
Fax: [ADDRESS_332116]  also be reported either by [CONTACT_756], email or by [CONTACT_272047], study 
coordinator, or other designated study personnel, or clinical research associate within twenty -four (24) 
hours of becoming aware of the SAE.  Follow up information must be reported as it becomes available, 
this may include records such as subject X -Rays, Admission and Discharge summaries, etc.  
7.4 Unanticipated Adverse E vents/Unanticipated Serious Adverse Events   
An unanticipated adverse event/serious adverse event is any unexpected untoward event or medical 
occurrence in a study subject that is not consistent with the known, predicted possible effects of the 
research pro tocol. An unanticipated adverse event/serious adverse event can therefore be any 
unanticipated, unfavorable, and unintended sign including an abnormal laboratory finding, 
symptom, or disease temporally associated with the study that was not listed in the p rotocol or 
consent form. This includes any experience that suggests a significant hazard, contraindication, 
side effect, or precaution.  
 
Unanticipated Adverse Events (UAEs) shall be reported to the Sponsor within two to five (2 -5) 
days of event notificatio n and Unanticipated Serious Adverse Events (SUAs) within 24 hours of 
event notification  (report unanticipated serious adverse events as soon as possible); to the IRB 
and to any medical oversight committees within seven (7) days of event notification unless 
institution guidelines require earlier reporting. Investigators should be vigilant in collecting as 
much information surrounding the event as possible, such that the investigator's best evaluation 
regarding the degree of impairment and the relationship between the surgical procedure and the 
adverse event can be made.  
VIII. Human Subject Pro tection Requirements  
The Principal Investigator (PI) is required to provide an Institutional Review Board (IRB) with all 
appropriate materials for review and approval prior to commencing any study related procedures.  The 
study may not be initiated unless/ until the IRB Committee provides written approval of the proposed 
clinical study  and an approved and IRB stamped Informed Consent Document .  Appropriate reports on 
the progress of this study by [CONTACT_079] [INVESTIGATOR_272024] . 
 
 
Page 26 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-[ADDRESS_332117] b e submitted to the Sponsor every three (3) years during 
the course of the study.  
IX. Regulatory Requirements  
Fortiva and Strattice are FDA 510(k) cleared for marketing in the [LOCATION_002] for hernia repair. No  
additional regulatory approvals are required to perform this study.  
X. Investigator’s Responsibilities  
The investigators are responsible for performing the study in full accordance with the protocol.  
Information regarding any centers participating in this study that do not comply with thes e standards will 
be documented.  
10.[ADDRESS_332118] will be given 
to all subjects by [CONTACT_1755]/or designee. Written informed consent will be obtained from each 
subject before any procedures or assessments that would not otherwise be required for the care of the 
subject are done and after the aims, methods, anticipated benefits, potential hazards, and insurance 
arrangeme nts in force are explained and the subject has been given sufficient time to ask questions and 
consider participation in the study. It will also be explained to the subjects that they are free to refuse 
entry into the study and free to withdraw from the st udy at any time without prejudice to future 
treatment. It is permissible for a third person (e.g., a family member) to be present during the explanation 
of the study.  
A copy of the informed consent document to be used will be submitted by [CONTACT_272048]. The original signed consent is retained in the subject’s 
study records, and a copy is provided to the subject.  
The ICF will comply with all applicable regulations governing protection of t he participants in the study, 
and include the basic elements specified in 21 CFR 50.25(a).  
 10.[ADDRESS_332119] assure that the privacy of the subjects, including their personal identity and all 
other personal medical information, will be maintained at all times. In CRFs and other documents or 
material, subjects will not be identified by [CONTACT_2249], but by [CONTACT_1209] (e.g., study allocated 
number). Personal medical information may be scrutinized for the pur pose of verifying data recorded in    
 
 
Page 27 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-[ADDRESS_332120]’s 
medical records. The subjects will be identified in the CRF with subject numbers. The Investigator should  
inform the subject that the records relevant to the study may be inspected by [CONTACT_272049], the FDA, or 
other persons as required by [CONTACT_2371].  
10.[ADDRESS_332121] th e investigator as 
needed.  
XI. Data Handling and Quality Assurance  
11.1 Case Report Forms (CRFs) and Data Clarification Forms (DCFs):  
As part of the responsibilities assumed by [CONTACT_55695], the Principal Investigator [INVESTIGATOR_11637] -
investigator agrees to maintain adequate case histories for the subjects treated as part of the research 
under this protocol.  The Principal Investigator [INVESTIGATOR_11637] -investigator agrees to maintain accurate CRFs/DCFs 
and source documentation as part of the subject case histories. The completed CRFs/DCFs are legal 
documents as they may be intended for submission to a regulatory agency as part of a regulatory 
submission. The data will be recorded on the CRFs/DCFs or other media as provided by [CONTACT_1034].  
a. These source documents may include chart notes, laboratory reports and ECG strips, X -Rays, CT 
scans and MRI. The reported data must be accurate, complete and verifiable from source 
documents.  
b. All CRFs should be completed legibly in black ink. CRFs may not be completed in pencil.  
c. All CRF information is to be filled in. If an item is not applicable or not done, this fact should be 
indicated by [CONTACT_45342] “NA” or “ND”, respectively. Blank spaces should not be present unless 
otherwise directed.  A correction should be made by [CONTACT_1022] 
a single line and the corrected information should be entered adjacent to the deleted item. 
The correction must be initialed and dated by [CONTACT_272050].  
d. The Investigator is to record all data relating to study procedures, treatment regimen 
administration, safety and efficacy data using the CRFs provided by [CONTACT_1034].  
e. All corrections on source documents as well as CRFs must be made so that the ori ginal data is 
not obscured in any way (i.e. use of correction fluid of any kind, correction tape, erasure or any 
form of obliteration of data is not permitted under any circumstances).  
f. Subject questionnaires may be recorded directly onto a CRF by [CONTACT_272051]. At study initiation, the Sponsor will communicate to 
the Investigator any CRFs that may serve as source documentation for the study.  
g. To ensure confidentiality, subjects will be identified in the CRFs on ly by [CONTACT_73976] (first, 
middle, last) and a unique study subject number.  
h. The Investigator’s signature [CONTACT_272061]. All electronic 
records and electronic signatures, if used, must comply with applicable laws and r egulations 
(e.g. FDA 21 CFR11).   
 
Page 28 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-[ADDRESS_332122] udy Monitor as soon as is practical  
after completion. One copy will remain at the site in the Principal Investigator [INVESTIGATOR_11637] -
investigator’s files.  
j. Data Clarification Forms (DCFs) are used to request additional information and/or clarification 
of data alread y entered on a specific case report form and with its completion with dated 
signature(s) serves as confirmation, clarification and/or correction of the original data entry.  
11.2 Monitoring of the Study:  
The Study  Monitor, as a representative of the Sponsor, has an  obligation to follow the study closely. In 
doing so, the Study Monitor will visit the Principal Investigator [INVESTIGATOR_11637] -investigator and study facility at 
periodic intervals, in addition to maintaining neces sary telephone and letter contact. The Study Monitor 
will maintain current personal knowledge of the study through observation, review of study records and 
source documentation, and discussion of the conduct of the study with the Principal Investigator [INVESTIGATOR_11637]-
investigator and staff.  
 
a. All aspects of the study will be carefully monitored by [CONTACT_272052] -GCP consolidated 
guideline and current standard operating procedures.  
b. Contact [CONTACT_272053], Inc.  
[ADDRESS_332123]  
Alachua, FL [ZIP_CODE] -2650  
[PHONE_5665] ext. 4344  
11.3 Inspection of Records:  
Principal Investigators or sub -investigators and institutions involved in the study will permit trial -related 
monitoring, audits, IRB review, and regulatory inspection(s) by [CONTACT_33035]. 
The Principal Investigator [INVESTIGATOR_11637] -investigator should promptly notify the Sponsor of any audits scheduled 
by [CONTACT_272054] a uthorities and promptly forward copi[INVESTIGATOR_82143].  
11.4 Regulatory Compliance:  
This study must be conducted in compliance with the Declaration of Helsinki and ICH -GCP.  In addition, all 
local, state, federal and institutio nal requirements will be adhered to, especially if they provide additional 
protection to the study subjects.  
11.5 Advertising:  
All potential advertising materials used to recruit subjects for this study will be submitted for  approval to 
the Sponsor and to the relevant IRB.  
 
 
 
 
Page 29 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
11.6 Protocol Amendments:  
Protocol amendments must be approved by [CONTACT_1201]/IEC prior to their implementation unless such changes 
are necessary to address immediate safety concerns for the subject.   
11.7 Adherence to Protocol:  
The final protocol sets forth how the study will be conducted.  
a. The Investigator is required to adhere to this protocol.  
b. Any reasonable alternatives, variations, or deviations from the protocol must first be 
approved by [CONTACT_1035] (if applicable) unless it is required for the successful 
management of safety issues relating to the subject.  
c. Any clarification to t he protocol will be documented in the study site’s Regulatory Binder.  
A protocol deviation occurs when the Investigator or subject has failed to adhere to protocol requirements.  
a. All deviations related to study inclusion or exclusion criteria, conduct of t he trial, subject 
management or subject assessment should be described.  
b. Protocol deviations should be appropriately documented. Specific categories to be 
documented include but are not limited to:  
i. Subjects who enter the study even though they do not satisf y the entry criteria  
ii. Subjects who complete study visit outside of specified window.  
iii. Subjects who do not complete required study procedures.  
c. Other protocol deviations to be considered include non -adherence to the protocol that 
results in a significant additional risk to the subject, or when there is non -
adherence to FDA (or other international regulatory agency) regulations and/or 
ICH/GCP guide lines.  
d. The Principal Investigator, sub -investigator, or designee must document and explain any 
protocol deviation in the subject’s source documentation.  
e. The IRB should be notified of all protocol deviations in a timely manner or according to their 
requir ements.  
f. Protocol deviations will also be documented by [CONTACT_272055] w ith the Investigator.  
g. The Principal Investigator [INVESTIGATOR_11637] -investigator may implement a change from the protocol 
without prior Sponsor and IRB approval only to eliminate an immediate hazard to a subject.  
h. If the Investigator believes that any exception to the protocol is justified for an individual 
subject or if the Investigator has a question concerning a subject who may not meet an entry 
criterion, they should contact [CONTACT_272056] (RTI Surgical).  
If the Sponsor is in agreem ent that an exception is justified, then a planned protocol 
deviation will be written and submitted to the applicable IRB for approval prior to 
implementation of the change per the IRB’s procedures.  The original document will remain 
with the subject’s sou rce file at the investigator’s site and the study Sponsor will be provided 
with copi[INVESTIGATOR_272025] (CTMF).  
11.8 Records Retention:  
At the conclusion of the study, all Essential Documents as listed in the ICH/GCP guidelines (including 
relevant medical/dental records and source documents, copi[INVESTIGATOR_3110], and ICFs) for all subjects for whom 
the Investigator has a signed Informed Consent Statement are retained by [CONTACT_737].  
 
Page 30 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
a. The retention period will be the grea ter of fifteen (15) years or the retention period 
dictated either by [CONTACT_16268], state or local regulations, or ICH/GCP 
guidelines.  
b. The Investigator must inform the Sponsor in writing for approval prior to the disposal of 
any study -related records even if the retention requirements as stated above have been 
met.  
c. If the Principal Investigator [INVESTIGATOR_272026], 
he/she or the current representative must contact [CONTACT_272057], 
as outlined above, to provide for continuing access by [CONTACT_272058], as needed.   
XII. Study Reporting Requirements  
12.1 Serious Adverse Events:  
By [CONTACT_4907], the Principal Investigator [INVESTIGATOR_11637] -investigator agrees to submit reports of SAEs 
and Adverse Reactions according to the timeline and method outlined in the protocol, IRB/IEC policy and 
applicable regulations.  
12.2 Continuing Annual Reviews:  
The Principal Investigator [INVESTIGATOR_11637] -investigator agrees to submit annual reports to his/her IRB/IEC as 
appropriate.  
12.3 Financial Disclosure:  
Principal Investigators and/or sub -investigators are required to provide financial disclosure infor mation to 
allow the Sponsor to submit the complete and accurate certification or disclosure statements required 
under Title 21 CFR 54 and 42 USC 1320a -7h, and any other applicable federal and state law or regulation.  
If any relevant changes occur througho ut the investigation and one (1) year following the completion of 
the study, the Principal Investigator [INVESTIGATOR_1238]/or sub -investigator must promptly provide the updated 
information to the Sponsor.  
 12.4 Sponsor Liability:  
 The Sponsor is not financially responsible for further testing/treatment of any medical condition that may 
be detected during the screening process.  
12.5 Investigator Documentation:  
Prior to beginning the study, the Principal Investigator [INVESTIGATOR_272027] t o comply with ICH/GCP guidelines and 
any applicable regulations by [CONTACT_44074], including but not limited to:  
 
a. An original Investigator Signature [CONTACT_272062].  
b. An IRB/IEC -approved Informed Consent Form, samples of site advertisements for recruitment 
for this study, and any other written information regarding this study that is to be provided to 
the subject or legal guardians.  
c. IRB/IEC approval of the Investigator, protocol, and Investigator’s Brochure (if applicable) . 
 
 
 
Page 31 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-16   
 Amendment 3   
 
 
d. Form FDA 1572, fully -executed, and all updates if applicable (or other international regulatory 
agency form, as applicable).  
e. Curricula Vitae and Human Subject Protection training for the Principal Investigator, each sub -
investigator, study coordinator , and any study staff participating in study related procedures 
and/or the informed consent process. Current licensure must be noted on the curricula vitae 
or a copy of the license provided. The curricula vitae must be signed and dated by [CONTACT_272059] -investigators within one year of study start -up, indicating that they are 
accurate and current.  
Unless otherwise established, updated, signed and dated curricula vitae for the Principal 
Investigator, each sub -investigator, and applicabl e study staff must be submitted every two (2) 
years and renewal of Human Protection training must be submitted every three (3) years 
during the course of the study.  
f. Financial disclosure information to allow the Sponsor to submit complete and accurate 
certification or disclosure statements required under Title [ADDRESS_332124] sixty (60) days prior to presentation or publication, in order to enable 
Sponsor to review and comment and take any steps necessary to protect its intellectual property rights, 
consistent with the Clinical Trial Agreement.  If RTI identifies in the p resentation or publication 
information that would have an adverse effect on an existing or potential patent application of RTI, the 
Principal Investigator [INVESTIGATOR_272028] (90) 
days from the dat e it receives notice from RTI in order to afford RTI an opportunity to mitigate such 
adverse effect.  
XIV. Investigator’s Final Report  
Following the completion of the study the Investigator shall participate i n the preparation of an integrated 
clinical and statistical final study report. The final report will include a general description of the conduct 
of the study including pertinent protocol deviations, subject withdrawals, and a discussion of AEs, safety 
data, and statistical analysis. This report will be approved and signed by [CONTACT_737].  
XV. Potential Financial Risks  
There are no additional financial risks to the subjects in connection with participation in this study.  
Participants will be compensated for their travel for follow up visits up to $100 per scheduled face to face 
visit.   
 
 
 
Page 32 of 34 
RTI Surgical Inc. CONFIDENTIAL  
Fortiva Porcine Dermis  
 Version# 4: 06-08-[ADDRESS_332125] their 
participation in this study.  The Investigator will immediately notify the Sponsor if s/he becomes aware of 
any such conflict of interest.   
XVII. Pu blication of Results  
At the completion of the evaluation the Investigator may publish the results in a peer - reviewed journal 
subject to the conditions set forth in Section [ADDRESS_332126] of the 
Sponsor, the Investigator will present the results at a significant AWR related meeting/symposium.  
17.1  Meetings  
Applicable meetings i nclude, but are not limited to America s Hernia Society/World Hernia Congress, 
Abdominal Wall Reconstruction Conference, and American College of Surgeons.    
17.[ADDRESS_332127] sixty (60) days prior to 
presentation or publication, in order to enable Sponsor to review and comment and take any steps 
necessary to protect its intellectual property ri ghts, consistent with Section 13 above and the terms of the 
clinical research agreement.  
XVIII. Study Registration  
This study will be registered by [CONTACT_272060].gov .  
 
 
 
 
 
                      RTI Surgical Inc. CONFIDENTIAL  Page 33 of 34 
 Fortiva Porcine Dermis  
Version# 4: 06-08-16 
Amendment 3  
                                                            
XX. References  
 
1. Catena F, Ansaloni L, Gazzotti F, Gagliardi S, Di Saverio S, D'Alessandro L, Pi[INVESTIGATOR_272029] (2007) Use of porcine dermal 
collagen graft (Permacol) for hernia repair in contaminated fields. Hernia 11 (1):57 -60. 
2. Chuo CB, Thomas SS (2008) Absorbable mesh and topi[INVESTIGATOR_272030].  J Plast Reconstr Aesthet Surg 61 (11):1378 -1381.  
3. Dallemagne B, Kohnen L, Perretta S, Weerts J, Markiewicz S, Jehaes C (2011) Laparoscopic repair of 
paraesophageal hernia. Long -term follow -up reveals good clinical outcome despi[INVESTIGATOR_272031]. Ann Surg 253 (2):291 -296.  
4. Dell RB, Holleran S, Ramakrishnan R (2002) Sample size determination. ILAR journal / National Research Council, 
Institute of Laboratory Animal Resources 43 (4):207 -213.  
5. Dunne JR, Malone DL, Tracy JK, Napolitano L M (2003) Abdominal wall hernias: risk factors for infection and 
resource utilization. J Surg Res 111 (1):78 -84. 
6. Fernandez Lobato R, Martinez Santos C, Ortega Deballon P, Fradejas Lopez JM, Marin Lucas FJ, Moreno Azcoita 
M (2001) Colocutaneous fistula du e to polypropylene mesh. Hernia 5 (2):107 -109.  
7. Gentile P, Colicchia GM, Nicoli F, Cervelli G, Curcio CB, Brinci L, Cervelli V (2011) Complex Abdominal Wall Repair 
Using a Porcine Dermal Matrix. Surg Innov.  
8. Harth KC, Broome AM, Jacobs MR, Blatnik JA, Zeinali F, Bajaksouzian S, Rosen MJ (2011) Bacterial clearance of 
biologic grafts used in hernia repair: an experimental study. Surg Endosc 25 (7):2224 -2229.  
9. Hashemi M, Peters JH, DeMeester TR, Huprich JE, Quek M, Hagen JA, Crookes PF, Theisen J, DeMees ter SR, Sillin 
LF, Bremner CG (2000) Laparoscopic repair of large type III hiatal hernia: objective followup reveals high 
recurrence rate. J Am Coll Surg 190 (5):553 -560; discussion 560 -551.  
10. Losanoff JE, Richman BW, Jones JW (2002) Entero -colocutaneous  fistula: a late consequence of polypropylene 
mesh abdominal wall repair: case report and review of the literature. Hernia 6 (3):[ADDRESS_332128] BT (2007) Meshes in hernia repair. Surg Technol Int 
16:[ADDRESS_332129] B, Jobe B, Polissar N, Mitsumori L, Nelson J, 
Swanstrom L (2006) Biologic prosthesis reduces recurrence after laparoscopic paraesophageal hernia 
repair: a multicenter, prospective , randomized trial. Ann Surg 244 (4):481 -490.  
13. Shaikh FM, Giri SK, Durrani S, Waldron D, Grace PA (2007) Experience with porcine acellular dermal collagen 
implant in one -stage tension -free reconstruction of acute and chronic abdominal wall defects. Worl d J Surg 
31 (10):1966 -1972; discussion [ADDRESS_332130] Rev  2008 ; CD006438.  
15. Lowe JB, Garza JR, Bowman JL, et al. Endoscopi[INVESTIGATOR_148445] "components separation" for closure of abdominal 
wall defects. Plast Reconstr Surg 2000; 105:720.  
16. Sailes FC, Walls J, Guelig D, et al. Ventral hernia repairs: 10 -year single -institution review at Thomas Jefferson 
University Hosp ital. J Am Coll Surg 2011; 212:119.    
17. Ramirez OM, Ruas E, Dellon AL. "Components separation" method for closure of abdominal -wall defects: an 
anatomic and clinical study. Plast Reconstr Surg 1990; 86:519.  
18. de Vries Reilingh TS, van Goor H, Rosman C,  et al. "Components separation technique" for the repair of large 
abdominal wall hernias. J Am Coll Surg 2003; 196:32.  
19. Shestak KC, Edington HJ, Johnson RR. The separation of anatomic components technique for the reconstruction 
of massive midline abdominal wall defects: anatomy, surgical technique, applications, and limitations 
revisited. Plast Reconstr Surg 2000; 105:731.  
 
 
                      RTI Surgical Inc. CONFIDENTIAL  Page 34 of 34 
 Fortiva Porcine Dermis  
Version# 4: 06-08-[ADDRESS_332131] read and understood the protocol and agree to implement the study in accordance with the procedures 
set forth in the protocol and in accordance with the Sponsor’s guidelines and all applicable government regulations 
and the International Conference on Harmonization Good Clinical Practice E6 (ICH/GCP).   
 
I will provide adequate protocol training to my associates, colleagues and employees assisting in the conduct of 
this study.  
 
I will obtain IRB or IEC approval of the Protocol and Subject ICF prior t o enrollment of subjects in the study.  I 
understand that any modifications to the protocol made during the course of the study must first be approved by 
[CONTACT_1201]/EC except when such modification is made to remove an immediate hazard to the subject.   
 
I will ensure that a fully executed Informed Consent Form is obtained from each subject prior to the initiation of 
study related procedures.   
 
I will report, within 24 hours of my knowledge, any SAE that occurs during the course of the study in accordance 
with the procedures described in the protocol.   
 
I will allow the Sponsor, RTI Surgical, Inc., and its agents, as well as the US Food and Drug  Administration (FDA) 
and other regulatory agencies, to inspect study facilities and pertinent records at reasonable times and in a 
reasonable manner, ensuring subject confidentiality.  If I am notified that this study is to be inspected by a regulatory 
agency, I will notify the Sponsor (RTI Surgical, Inc.) and the IRB/EC as soon as possible thereafter (no later than one 
week).   
 
_________________________     ________________  
Principal Investigator [INVESTIGATOR_236091]  
 
_____________________________  
Printed Pr incipal Investigator Name  
 
 
 
 
 